GeneMatrix Inc Cash Flow Conversion Efficiency

Latest as of September 2025: 0.027x

GeneMatrix Inc cash flow conversion efficiency. Based on the latest financial reports, GeneMatrix Inc (109820) has a cash flow conversion efficiency ratio of 0.027x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩500.19 Million ≈ $338.97K USD) by net assets (₩18.32 Billion ≈ $12.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GeneMatrix Inc (2014–2024)

Cash flow conversion efficiency of GeneMatrix Inc from 2014 to 2024. This chart illustrates how GeneMatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GeneMatrix Inc stock price for real-time trading data and today's change.

GeneMatrix Inc Cash Flow Conversion Ratio Explained

GeneMatrix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GeneMatrix Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GeneMatrix Inc ranked by their cash flow conversion efficiency. Also see GeneMatrix Inc (109820) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Australian Rare EARTHS Ltd AU:AR3	-0.007x
Softcen Co. Ltd KQ:032680	0.023x
High-Tech Metals Ltd AU:HTM	-0.072x
Law Debenture Corp LSE:LWDB	0.023x
STS Group AG XETRA:SF3	0.369x
Hubei Geoway Investment Co Ltd SHG:600462	0.893x
Shenzhen Tellus Holding Co Ltd SHE:200025	-0.032x
The Beachbody Company, Inc. NASDAQ:BODI	-0.147x

Annual Cash Flow Conversion Efficiency for GeneMatrix Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of GeneMatrix Inc from 2014 to 2024. Review GeneMatrix Inc (109820) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩19.23 Billion ≈ $13.03 Million	₩-200.12 Million ≈ $-135.62K	-0.010x	+89.73%
2023-12-31	₩23.15 Billion ≈ $15.69 Million	₩-2.35 Billion ≈ $-1.59 Million	-0.101x	-139.49%
2022-12-31	₩24.19 Billion ≈ $16.39 Million	₩-1.02 Billion ≈ $-693.53K	-0.042x	-140.59%
2021-12-31	₩32.32 Billion ≈ $21.90 Million	₩3.37 Billion ≈ $2.28 Million	0.104x	-22.75%
2020-12-31	₩33.39 Billion ≈ $22.63 Million	₩4.51 Billion ≈ $3.05 Million	0.135x	+190.33%
2019-12-31	₩15.25 Billion ≈ $10.33 Million	₩-2.28 Billion ≈ $-1.54 Million	-0.149x	+40.89%
2018-12-31	₩10.83 Billion ≈ $7.34 Million	₩-2.74 Billion ≈ $-1.86 Million	-0.253x	-57.59%
2017-12-31	₩11.06 Billion ≈ $7.49 Million	₩-1.77 Billion ≈ $-1.20 Million	-0.160x	-436.38%
2016-12-31	₩12.48 Billion ≈ $8.46 Million	₩-373.25 Million ≈ $-252.95K	-0.030x	+49.30%
2015-12-31	₩10.04 Billion ≈ $6.80 Million	₩-591.96 Million ≈ $-401.17K	-0.059x	+49.01%
2014-12-31	₩11.89 Billion ≈ $8.06 Million	₩-1.38 Billion ≈ $-931.91K	-0.116x	--

About GeneMatrix Inc

KQ:109820 Korea Diagnostics & Research

Market Cap

$18.98 Million

₩28.01 Billion KRW

Market Cap Rank

#25136 Global

#1844 in Korea

Share Price

₩1403.00

Change (1 day)

-1.13%

52-Week Range

₩1314.00 - ₩2545.00

All Time High

₩33900.00